Biomarker Research and Evaluation for Clinical Implementation and Supporting Systems Enhancement (BRECISE)
Financed by : European Comission and EFPIA
Program: Innovative Health Initiative JU Call 7
Project Reference: 101194784
Role in the project: Partner
Duration: January 2025 to December 2029
Contact: Bernardo Herrera Imbroda
Implementation Centre: Hospital Universitario Virgen de la Victoria
Research group of IBIMA involved: Translational Research in Genitourinary Oncology
ABSTRACT
BRECISE is a Public-Private Partnership Project, co-funded by the Innovative Health Initiative (IHI) of the European commission aiming at creating a collaborative ecosystem to accelerate the clinical validation of Next-Generation Sequencing (NGS)-based, multi-modality Artificial Intelligence (AI) oncology biomarkers and related technologies. By addressing technical and regulatory challenges, the consortium unites diverse expertise and resources to validate novel prostate and bladder cancer biomarkers, ensuring their efficacy and clinical utility. This initiative aligns with the goal of advancing precision medicine in oncology, ultimately improving patient outcomes and streamlining personalized cancer care.
BRECISE’s primary objective is to enhance biomarker-driven approaches for patient risk stratification, disease progression prediction, and treatment response assessment, within the framework of precision medicine. The project addresses the current challenge of limited access to clinically validated prognostic and predictive biomarkers in oncology. By providing healthcare professionals with NGS-based, multi-modality AI oncology biomarkers, BRECISE aims to enable precise disease risk assessment and informed treatment selection, contributing to more personalized and effective patient care.
The impact of BRECISE is transformative, aiming to revolutionize risk assessment and treatment selection in oncology, facilitating the implementation of precision medicine. This will significantly reduce unnecessary and ineffective treatments, optimizing patient care and minimizing side effects. The validated biomarker technologies empower researchers to develop safer and more effective personalized treatments, advancing precision medicine. These advancements will enhance the competitiveness of European health industries, positioning them at the forefront of innovation and healthcare excellence. Overall, BRECISE is expected to significantly improve patient outcomes, enhance healthcare efficiency, and bolster the global standing of European health industries.
Partners
-
-
- South East Technological University
- 3D-PharmXchange BV
- Agenzia di Tutela della Salute della Brianza
- Associazione Italiana Malati di Cancro, Parenti e Amici (AIMAC)
- Atrys Health, SA
- Bioclavis Limited
- Biocomputing Platforms Ltd Oy
- Bridg OU
- Crown Bioscience Netherlands BV
- Dedalus Italia S.p.A.
- Elliniki Omospodia Karkinou Ell OK (Hellenic Cancer Federation)
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
-
-
-
- European Alliance for Personalised Medicine
- Genomate Health Hungary Kft
- HUB Organoids BV
- Mutualité Fonction Publique Action Santé Social (MFPASS)
- OHMX.bio
- Philips Electronics Nederland BV
- PredictBy Research and Consulting S.L.
- Region Stockholm
- Servicio Andaluz de la Salud
- Stichting Radboud Universitair Medisch Centrum (Radboudumc)
- UAB Cureline Baltic
- Universidad Complutense de Madrid (UCM)
- Västra Götalandsregionen (VGR)
-
Project News
The BRECISE Project: Driving Precision Oncology
The Biomedical Research Institute of Málaga and Nanomedicine Platform (IBIMA) is participating in the groundbreaking European project BRECISE, which aims to revolutionize the diagnosis and treatment of prostate and bladder cancer through advanced biomarkers and...